NEO100 yields 21% radiographic response & 44% 6mo PFS in recurrent IDH1-mutant gliomas

NEONC TECHNOLOGIES HOLDINGS, INC.

Radiographic response rate of 21% (5/24) in recurrent Grade III/IV IDH1-mutant astrocytoma, exceeding <8% benchmark for salvage therapies.
Six-month progression-free survival (PFS-6) of 44% (8/18 evaluable) vs historical 21-31%.
33% of patients (8/24) alive ≥18 months post-NEO100 initiation; median overall survival 88 months.
No significant toxicity with chronic intranasal dosing; enrollment completed at 25 patients.
CEO calls data a potential paradigm shift; company advancing to Phase 2b/3 and global trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.